---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-006600"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-01-11T23:59:59+00:00"
generated_at: "2026-06-07T00:45:14.951350+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron partners with CrossLink to add ~650 sales reps for ZYNRELEF through 2028

## Summary
- CrossLink adds at least 325 sales reps by July 2024 and 650 by Jan 2025.
- Fixed-fee per vial compensation based on growth over baseline period.
- Up to 1,666,670 shares of common stock and $5M in milestone payments.
- Five-year term ending Dec 2028, renewable annually.
- Partnership targets orthopedic indications; initial regional rollout expands nationally.

## SEC filing metadata
- accession: 0001193125-24-006600
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-01-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/0001193125-24-006600-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/d636605d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-006600
- JSON: https://secwatch.observer/filing/0001193125-24-006600.json
- Plain text: https://secwatch.observer/filing/0001193125-24-006600.txt

## Key facts
- Material Agreements
  HERON THERAPEUTICS, INC. /DE/ entered into Co-Promotion Agreement with Crosslink Network, LLC valued at Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5 (effective 2024-01-05).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Crosslink Network, LLC
  - Value: Up to 1,666,670 shares of common stock; cash base compensation on fixed-fee per vial basis; up to $5
  - Effective: 2024-01-05
  source text: On January 5, 2024, Heron Therapeutics, Inc. (the “Company”) and Crosslink Network, LLC (“Crosslink”) entered into a Co-Promotion Agreement (the “Co-Promotion Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/818033/000119312524006600/0001193125-24-006600-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.